Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06682442 · ClinicalTrials.gov registry record · NA
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
A NA study of Nasopharyngeal Carcinoma and Nasopharyngeal Cancer, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT06682442 is a NA study of Nasopharyngeal Carcinoma and Nasopharyngeal Cancer that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 66 participants, below the 90-participant average among 7 other Nasopharyngeal Carcinoma trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06682442, a NA study of Nasopharyngeal Carcinoma and Nasopharyngeal Cancer, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial tests the effect of induction chemotherapy response-guided radiation (de-escalated intensity-modulated radiation therapy \[IMRT\]) compared to standard IMRT in patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. Intensity-modulated radiation therapy (IMRT) is an advanced form of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Radiation therapy sometimes causes unwanted symptoms or side effects, including late effects such as hearing loss and dental problems. The severity of the side effects is related to the radiation dose received and the amount of tissue that received radiation. De-escalation IMRT uses lower doses of radiation based on a good response to induction chemotherapy. Giving de-escalated IMRT may be as effective as standard doses of IMRT in treating patients with EBV-associated nasopharyngeal cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- RADIATION Intensity-Modulated Radiation Therapy (IMRT)
- PROCEDURE Radiographic Imaging
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2032-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06682442
The ClinicalTrials.gov registry entry for NCT06682442 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 7 other Nasopharyngeal Carcinoma trials with a reported enrollment target (27% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Nasopharyngeal Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT06682442 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06682442 about?
NCT06682442 is a clinical study titled "Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma". This clinical trial tests the effect of induction chemotherapy response-guided radiation (de-escalated intensity-modulated radiation therapy \[IMRT\]) compared to standard IMRT in patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. Intensity-modulated radiation therapy (IMRT) is...
What is the current status of trial NCT06682442?
This trial is currently recruiting. It is a NA study. The enrollment target is 66 participants. The study started on 2025-03-18. Estimated completion is 2032-03-31.
What conditions does trial NCT06682442 study?
This clinical trial studies the following conditions: Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Nasopharyngeal Cancer Stage.
What interventions are being tested in trial NCT06682442?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Intensity-Modulated Radiation Therapy (IMRT) (RADIATION), Radiographic Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT06682442?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06682442 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nasopharyngeal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
RECRUITING · Phase 2
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
ACTIVE NOT RECRUITING · Phase 1
-
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
ACTIVE NOT RECRUITING · Phase 1
-
Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.